

**IMPLEMENTATION RESEARCH PROGRAM WITH  
POINT-OF-CARE TESTS FOR  
HIV AND CO-INFECTIONS**



**EVALUATION AND INNOVATION IN INDIAN, SOUTH  
AFRICAN AND CANADIAN HEALTH SYSTEMS**

**NITIKA PANT PAI, MD, MPH, PhD**

*Assistant Professor*

*Clinical Epidemiology & Infectious Diseases*


*Faculty of Medicine*

*Email: [nitika.pai@mcgill.ca](mailto:nitika.pai@mcgill.ca)*



# CONFLICTS OF INTEREST

We have no conflicts of interest with industry.



# POINT-OF-CARE TESTS

1


Program on POCTs

2

Background work

3

Multiplex /Self testing



*“There is something better than science. That is science with a moral compass. Science that contributes to the social equity. Science in the service of humanity.”*

**William H Foege, MD**

# Vision and Mission

## Vision:

Innovative, expedited **public health screening strategies** with **point-of-care tests (POCTs)** for marginalized populations

## Mission:

Impact public health, global public policy

New methodologies and evidence



# POCT-generations



# Study I: Oral test accuracy

- # India's HIV epidemic was at its peak; debate
  - # Inadequate screening of at risk population
- # Screening by conventional methods;
  - # Finger stick based POC tests;
  - # **No data on accuracy** of Oral tests from rural settings
  - # Sevagram, Rural Indian hospital India





# Evaluation of Diagnostic Accuracy, Feasibility and Client Preference for Rapid Oral Fluid-Based Diagnosis of HIV Infection in Rural India

Nitika Pant Pai<sup>1\*</sup>, Rajnish Joshi<sup>2</sup>, Sandeep Dogra<sup>3</sup>, Bharati Taksande<sup>2</sup>, S. P. Kalantri<sup>2</sup>, Madhukar Pai<sup>4</sup>, Pratibha Narang<sup>2</sup>, Jacqueline P. Tulsy<sup>5</sup>, Arthur L. Reingold<sup>6</sup>

<sup>1</sup> Immunodeficiency Service, Montreal Chest Institute, McGill University Health Center, Montreal, Canada, <sup>2</sup> Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India, <sup>3</sup> Acharya Shri Chander College of Medical Sciences, Jammu, India, <sup>4</sup> Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada, <sup>5</sup> Department of Internal Medicine, University of California at San Francisco, San Francisco, California, United States of America, <sup>6</sup> Division of Epidemiology, University of California at Berkeley, Berkeley, California, United States of America

$S_n=100$  (95%CI:98,100)  
 $S_p=100$ (95%CI 99,100)  
 Preference 87% first time

Table 2. Diagnostic accuracy of the OraQuick HIV-1/2 rapid test performed on oral mucosal fluid specimens

	ELISA+Western Blot positive	ELISA+Western Blot negative	Total
Oral fluid test positive	146	0	146
Oral fluid test negative	0	304	304
	146	304	450

Sensitivity = 100% (95% CI 98, 100)

Specificity = 100% (95% CI 99, 100)

Positive predictive value = 100%

Negative predictive value = 100%

Positive likelihood ratio = NA

Negative likelihood ratio = 0

doi:10.1371/journal.pone.0000367.t002

# Study II: Oraquick II: Pregnant women in labour

## Problem

- ❖ About 50% women presented “unregistered”
- ❖ HIV testing not offered round-the-clock
- ❖ ART was ineffectively delivered
- ❖ **Last window of opportunity to prevent HIV transmission**

## Labour room



# Impact

## Impact of Round-the-Clock, Rapid Oral Fluid HIV Testing of Women in Labor in Rural India

Nitika Pant Pai<sup>1\*</sup>, Ritu Barick<sup>2</sup>, Jacqueline P. Tulsy<sup>3</sup>, Poonam V. Shivkumar<sup>2</sup>, Deborah Cohan<sup>3</sup>, Shriprakash Kalantri<sup>2</sup>, Madhukar Pai<sup>4</sup>, Marina B. Klein<sup>1</sup>, Shakuntala Chhabra<sup>2</sup>

**1** Division of Infectious Diseases and Immunodeficiency Service, Montreal Chest Institute, McGill University Health Center, Montreal, Canada, **2** Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India, **3** Positive Health Program, Division of Internal Medicine, University of California San Francisco, San Francisco, California, United States of America, **4** Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada

**Funding:** This study was in part supported by the Canadian HIV Trials Network. NPP is supported by a fellowship from the Canadian HIV Trials Network (CTN). CTN had no role in the design, conduct, analysis, interpretation of data, manuscript preparation, nor in the decision to submit this manuscript for a publication.

**Competing Interests:** Deborah Cohan has an investigator-initiated research award from Pfizer Pharmaceuticals.

**Academic Editor:** David Celentano, Johns Hopkins University, United States of America

**Citation:** Pai NP, Barick R, Tulsy JP, Shivkumar PV, Cohan D, et al. (2008) Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. PLoS Med 5(5): e92. doi:10.1371/journal.pmed.0050092


### ABSTRACT

#### Background

Testing pregnant women for HIV at the time of labor and delivery is the last opportunity for prevention of mother-to-child HIV transmission (PMTCT) measures, particularly in settings where women do not receive adequate antenatal care. However, HIV testing and counseling of pregnant women in labor is a challenge, especially in resource-constrained settings. In India, many rural women present for delivery without any prior antenatal care. Those who do get antenatal care are not always tested for HIV, because of deficiencies in the provision of HIV testing and counseling services. In this context, we investigated the impact of introducing round-the-clock, rapid, point-of-care HIV testing and counseling in a busy labor ward at a tertiary care hospital in rural India.

#### Methods and Findings

After they provided written informed consent, women admitted to the labor ward of a rural teaching hospital in India were offered two rapid tests on oral fluid and finger-stick specimens (OraQuick Rapid HIV-1/HIV-2 tests, OraSure Technologies). Simultaneously, venous blood was



**Figure 1.** Flow of Participants Through the Study  
 doi:10.1371/journal.pmed.0050092.g001


## Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis

Nitika Pant Pai<sup>1</sup>, Jacqueline Peterson Tulsy<sup>2</sup>, Deborah Cohan<sup>3</sup>, John M. Colford, Jr<sup>1</sup> and Arthur L. Reingold<sup>1</sup>

<sup>1</sup> McGill University Health Centre, Division of Infectious Diseases & Immunodeficiency Service, Montreal Chest Institute, QC Canada

<sup>2</sup> Positive Health Program at San Francisco General Hospital, University of California, San Francisco, CA, USA

<sup>3</sup> Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA



**Figure 2** Forest plot of sensitivity and specificity for blood-based and oral rapid HIV tests. The point estimates of sensitivity and specificity for each study are shown as solid circles and squares with error bars (95% confidence intervals). Solid squares represent oral rapid tests and solid circles represent blood-based rapid tests.



Nitika Pant Pai  
McGill University Health Centre,  
Division of Infectious Diseases  
& Immunodeficiency Service, Montreal  
Chest Institute, 3650 St Urbain Street,  
Montreal, Quebec, H2X 2P4, Canada

### Oral fluid-based rapid HIV testing: issues, challenges and research directions

'... it is hoped that detection of (HIV-infected) individuals with high-quality, rapid, accurate point-of-care oral HIV tests will enable provision of early, timely and highly effective ART or expedite triage to care and prevention.'

*Ergonomics* 2007, 50(4), 325-328



## **Study III: CIHR-CTN SP 243 trial: Montreal**

**Simultaneous Timed Triple Screening (SiTTS)  
strategy (2009-2011)  
with POC tests for HIV, Hepatitis B and Syphilis in  
early pregnancy**



ORIGINAL RESEARCH ARTICLE

## Simultaneous triple point-of-care testing for HIV, syphilis and hepatitis B virus to prevent mother-to-child transmission in India

**N P Pai** MD MPH PhD\*, **J Kurji** MSc<sup>†\*\*</sup>, **A Singam** MD<sup>†\*\*</sup>, **R Barick** MD<sup>‡</sup>, **Y Jafari**<sup>§</sup>, **M B Klein** MD MSc\*,  
**S Chhabra** MD<sup>‡</sup> and **P Shivkumar** MD<sup>‡</sup>

\*Division of Clinical Epidemiology & Division of Infectious Diseases, McGill University Health Center, Montreal; <sup>†</sup>Dala Lana School of Public Health, University of Toronto, Toronto, Canada; <sup>‡</sup>Mahatma Gandhi Institute of Medical Sciences, Sevagram, India; <sup>§</sup>Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada

**Summary:** An innovative simultaneous triple point-of-care (STPOC) screening strategy for syphilis, hepatitis B and HIV with Determine<sup>®</sup> tests was offered to pregnant women presenting for antenatal care and evaluated for feasibility and preference in rural India. Of 1066 participants approached, 1046 consented, of which 1002 (96.0%) completed the strategy. Only 9% reported any history of testing in their current pregnancy. With STPOC screening, 989 women (98.7%) tested negative and 13 had preliminary positive results for infection. The total time taken was 45 minutes per participant. Mothers and infants were provided prophylaxis/treatment for HIV, syphilis and hepatitis B, with interventions initiated within 3–5 days. STPOC was preferred by 99.3% (95%CI: 98.8–99.8%) of participants, facilitated early simultaneous screening for the three infections, timely initiation of prophylaxis/treatment and was feasible in this rural setting. These data suggest that multiplexed STPOC screening for syphilis, hepatitis B and HIV in pregnancy would be desirable for women in rural India.

**Keywords:** HIV, syphilis, hepatitis B, point-of-care test, screening, pregnancy, antenatal care, rural, India



STUDY IV & V :  
COMPARATIVE EVALUATION OF  
MULTIPLEX TESTING STRATEGY IN  
CANADA & INDIA





# STUDY IV: MUMBAI URBAN POOR MULTIPLEX STUDY

- STD clinic attendees
- Mumbai, India

# STUDY V: MULTIPLEX STUDY: MONTREAL



- Injection drug users
- Community Clinics
- Montreal, Canada

# MULTIPLEX COMPARATIVE TABLE

CATEGORY	MUMBAI	MONTREAL
<b>Population</b>	375 STI clinic attendees	109 IDU
<b>Demographics</b>		
•Gender	83% males	67.9% males
•Age (mean)	31.2 years	
<b>History of testing</b>		
•HIV	48%	96.3%
•HBV	1.62%	83.8%
•HCV	1.89%	94.3%
•Syphilis	2.7%	58.7%
<b>Sensitivity</b>		
•HIV	100% [95%, CI: 94.8, 100]	100% [95%, CI: 47.3, 100]
•HBV	13.3% [95%, CI: 6.6, 23.2]	n/a
•HCV	50% [95%, CI: 1.26, 98.74]	80.4% [95%, CI: 66.1, 90.6]
•Syphilis	86.1% [95%, CI: 70.5, 95.3]	100% [95%, CI: 22.4, 100]

CATEGORY	MUMBAI	MONTREAL
<b>Specificity</b>		
•HIV	99.7% [95%, CI: 98.3, 100]	100% [95%, CI: 97.2, 100]
•HBV	99.3% [95%, CI: 98.5, 99.9]	100% [95%, CI: 97.3, 100]
•HCV	99.7% [95%, CI: 98.5, 100]	85.3% [95%, CI: 73.8, 93.0]
•Syphilis	85.2% [95%, CI: 80.9, 88.8]	98.1% [95%, CI: 93.3, 99.8]
<b>Prevalence</b>		
•HIV	14.9% (56)	3.7% (4)
•HBV	20% (75)	n/a
•HCV	0.5% (2)	43% (46)
•Syphilis	9.87% (37)	1.9% (2)
<b>Concordance</b>		
•HIV	99.7% ( $\kappa = 0.99$ )	n/a
•HBV	98.9% ( $\kappa = 0.79$ )	n/a
•HCV	100% ( $\kappa = 1$ )	n/a
•Syphilis	97.3% ( $\kappa = 0.92$ )	n/a
<b>Preference</b>	61%	n/a

# Evidence from other studies?

Meta-analyses

# CIHR funded POC tests for Hepatitis C, Hepatitis B, Syphilis: F 1000 citation

## Annals of Internal Medicine

Established in 1927 by the American College of Physicians

REVIEW

Annals of Internal Medicine

### Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C

A Systematic Review and Meta-analysis

Sushmita Shivkumar, MSc; Rosanna Peeling, PhD; Yalda Jafari, MSc; Lawrence Joseph, PhD; and Nitika Pant Pai, MD, MPH, PhD

**Background:** 170 million persons worldwide are infected with hepatitis C, many of whom are undiagnosed. Although rapid diagnostic tests (RDTs) and point-of-care tests (POCTs) provide a time- and cost-saving alternative to conventional laboratory tests, their global uptake partly depends on their performance.

**Purpose:** To meta-analyze the diagnostic accuracy of POCTs and RDTs to screen for hepatitis C.

**Data Sources:** MEDLINE, EMBASE, BIOSIS, and Web of Science (1992 to 2012) and bibliographies of included articles.

**Study Selection:** All studies evaluating the diagnostic accuracy of POCTs and RDTs for hepatitis C in adults (aged  $\geq 18$  years).

**Data Extraction:** Two independent reviewers extracted data and critiqued study quality.

**Data Synthesis:** Of 19 studies reviewed, 18 were meta-analyzed and stratified by specimen type (whole blood, serum, plasma, or oral fluid) or test type (POCT or RDT). Sensitivity was similarly high in POCTs of whole blood (98.9% [95% CI, 94.5% to 99.8%]) and

serum or plasma (98.9% [CI, 96.8% to 99.6%]), followed by RDTs of serum or plasma (98.4% [CI, 88.9% to 99.8%]) and POCTs of oral fluid (97.1% [CI, 94.7% to 98.4%]). Specificity was also high in POCTs of whole blood (99.5% [CI, 97.5% to 99.9%]) and serum or plasma (99.7% [CI, 99.3% to 99.9%]), followed by RDTs of serum or plasma (98.6% [CI, 94.9% to 99.6%]) and POCTs of oral fluid (98.2% [CI, 92.2% to 99.6%]).

**Limitation:** Lack of data prevented sensitivity analyses of specific tests.

**Conclusion:** Data suggest that POCTs of blood (serum, plasma, or whole blood) have the highest accuracy, followed by RDTs of serum or plasma and POCTs of oral fluids. Given their accuracy, convenience, and quick turnaround time, RDTs and POCTs may be useful in expanding first-line screening for hepatitis C.

**Primary Funding Source:** Canadian Institutes of Health Research.

*Ann Intern Med.* 2012;157:558-566.

For author affiliations, see end of text.

[www.annals.org](http://www.annals.org)

AJG The American Journal of  
GASTROENTEROLOGY

### Rapid Point-of-Care First-Line Screening Tests for Hepatitis B Infection: A Meta-Analysis of Diagnostic Accuracy (1980–2010)

Sushmita Shivkumar, MSc<sup>1,2</sup>, Rosanna Peeling, PhD<sup>3</sup>, Yalda Jafari, MSc<sup>1</sup>, Lawrence Joseph, PhD<sup>2</sup> and Nitika Pant Pai, MD, MPH, PhD<sup>1,4</sup>

**OBJECTIVES:** Three-hundred fifty million people worldwide are chronically infected with Hepatitis B, with four million acute infections annually. With infection concentrated in hard-to-reach populations and low resource settings, rapid point-of-care (POC) tests offer an efficient screening alternative to laboratory tests. We conducted a meta-analysis to evaluate accuracy of rapid POC tests screening for Hepatitis B.

**METHODS:** Two reviewers searched four databases, critiqued quality. A hierarchical Bayesian meta-analysis correcting for imperfect reference standards was used. Based on components of the antigen-antibody response, 17 studies were stratified into three subgroups: (i) Hepatitis B surface antigen (HBsAg) tests; (ii) anti-HBsAg tests, and (iii) HBs+eAg tests. Further, we pooled estimates on individual tests with sufficient data.

**RESULTS:** In subgroup 1, the pooled sensitivity (Sn) was 94.76% (95% credible interval (CrI): 90.08–98.23%) and specificity (Sp) was 99.54% (95% CrI: 99.03–99.95%). The Determine test reported a pooled Sn 98.2% (95% CrI: 94.7, 99.9) and Sp 99.9% (95% CrI: 99.3, 100); in subgroup 2, Sn 93.2% (95% CrI: 85.1, 98.5), Sp 93.1% (95% CrI: 81.9, 99.9); and in subgroup 3, the Binax test showed Sn 95.5% (95% CrI: 88.9, 99.4), Sp 99.8% (95% CrI: 99.3, 100).

**CONCLUSIONS:** HBsAg tests, including Determine, and the HBs+eAg test, Binax showed high accuracy. Improvements in sensitivity of antibody-based tests will enhance their potential for global first-line screening.

**SUPPLEMENTARY MATERIAL** is linked to the online version of the paper at <http://www.nature.com/ajg>

*Am J Gastroenterol* advance online publication, 29 May 2012; doi:10.1038/ajg.2012.141

REVIEW

# Are *Treponema pallidum* Specific Rapid and Point-of-Care Tests for Syphilis Accurate Enough for Screening in Resource Limited Settings? Evidence from a Meta-Analysis

Yalda Jafari<sup>1</sup>, Rosanna W. Peeling<sup>2</sup>, Sushmita Shivkumar<sup>1</sup>, Christiane Claessens<sup>3</sup>, Lawrence Joseph<sup>1,4</sup>, Nitika Pant Pai<sup>4\*</sup>

**1** Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada, **2** London School of Hygiene and Tropical Medicine, London, United Kingdom, **3** Institut national de santé publique (INSPQ), Montréal, Canada, **4** Division of Clinical Epidemiology, Department of Medicine, McGill University and MUHC, Montréal, Canada

## Abstract

**Background:** Rapid and point-of-care (POC) tests for syphilis are an invaluable screening tool, yet inadequate evaluation of their diagnostic accuracy against best reference standards limits their widespread global uptake. To fill this gap, a systematic review and meta-analysis was conducted to evaluate the sensitivity and specificity of rapid and POC tests in blood and serum samples against *Treponema pallidum* (TP) specific reference standards.

**Methods:** Five electronic databases (1980–2012) were searched, data was extracted from 33 articles, and Bayesian hierarchical models were fit.

**Results:** In serum samples, against a TP specific reference standard point estimates with 95% credible intervals (CrI) for the sensitivities of popular tests were: i) Determine, 90.04% (80.45, 95.21), ii) SD Bioline, 87.06% (75.67, 94.50), iii) VisiTect, 85.13% (72.83, 92.57), and iv) Syphicheck, 74.48% (56.85, 88.44), while specificities were: i) Syphicheck, 99.14% (96.37, 100), ii) VisiTect, 96.45% (91.92, 99.29), iii) SD Bioline, 95.85% (89.89, 99.53), and iv) Determine, 94.15% (89.26, 97.66). In whole blood samples, sensitivities were: i) Determine, 86.32% (77.26, 91.70), ii) SD Bioline, 84.50% (78.81, 92.61), iii) Syphicheck, 74.47% (63.94, 82.13), and iv) VisiTect, 74.26% (53.62, 83.68), while specificities were: i) Syphicheck, 99.58% (98.91, 99.96), ii) VisiTect, 99.43% (98.22, 99.98), iii) SD Bioline, 97.95% (92.54, 99.33), and iv) Determine, 95.85% (92.42, 97.74).

**Conclusions:** Rapid and POC treponemal tests reported sensitivity and specificity estimates comparable to laboratory-based treponemal tests. In resource limited settings, where access to screening is limited and where risk of patients lost to follow up is high, the introduction of these tests has already been shown to improve access to screening and treatment to prevent stillbirths and neonatal mortality due to congenital syphilis. Based on the evidence, it is concluded that rapid and POC tests are useful in resource limited settings with poor access to laboratories or screening for syphilis.

**Editor:** D. William Cameron, University of Ottawa, Canada

**Received** January 15, 2012; **Accepted** December 17, 2012; **Published** February 26, 2013

February 2013 | Volume 8 | Issue 2 | e54695

# POINT-OF-CARE TESTS

1

Program on POCTs

2

Background

3

Studies on self testing



**Worldwide**, six out of ten **individuals do not know** their HIV sero-status

Conventional facility-based testing


- Visibility and lack of confidentiality
- Long wait times
- Delay in receipt of results and linkages to treatment
- Stigma and Discrimination
- **In North America**, **25 - 30%** are lost to follow up  
**40%** present late with AIDS

# SELF TESTING



- A. Privacy and confidentiality
- B. Decreases stigma and discrimination





**HELP US EVALUATE A RAPID HIV TEST!**

Investigators:  
Dr. Nikita Patel  
Dr. Pierre-Paul Teller

Are you:

- > A student at McGill University?
- > 18 years or older?
- > Interested in trying out a new rapid HIV test?

McGill Student Health Services and the McGill University Health Centre are recruiting participants for a new study.

Call Student Health Services at 514-398-6017 to make an appointment with a nurse.

Participants will be



GAIL AND SALLE DE C

INTERNATION SERVICES AU

OFFICE FOR SERVICE DE L

**100%** Agreement between student-led self testing and nurse-led POC test

**81%** preferred self-test over conventional lab-based testing

**98%** found self-tests convenient

**84%** oral self-tests non invasive and pain free

**71%** willingness to buy them over-the-counter

**65%** expressed willingness to follow up with lab-based confirmatory tests if self-tests were offered

## **Preferred post-test counseling options:**

- Phone and internet: 43%
- Community clinics: 41%
- Pharmacies: 16%

# IS THERE A PLACE FOR SELF TESTING IN THE CANADIAN HEALTH SYSTEM?

- Financial burden of treating HIV infected individuals 4 billion
- 64.2% of newly diagnosed advanced to AIDS in one year.
- New infections will cost CAD\$ 3,175 per year (2,250-4,100)
- Direct health cost, economic and quality of life LOSS amounted to \$14,453 per asymptomatic HIV-infected person, failure to detect and treat infected individuals at an early stage

*"If people find out they're HIV positive, they're going to take precautions they might not otherwise," says Paol.*

# Bring HIV home test to Canada: experts

Quick device  
ready for sale in  
Canada on Monday



Milka Paol of the St. Catharines Health Centre has determined that the OraQuick home HIV test is 100-per-cent accurate in high-risk groups.

"If you're HIV positive, you can go out and get treated with medicines to keep that virus from multiplying and you're much more going to live a longer and healthier life span."

She says the new version of which she's testing is an advance on the first generation of HIV tests through unimpaired use, he explained.

"If people find out that they're HIV positive, they're going to take precautions, because they might not otherwise," he said.

In 2007, Merck launched the first product involving this device using a rapid HIV test kit.

the Village. The clinic was not testing for free and the major issue is that everything is done anonymously.

To date, more than 1,000 people have been tested, with a 100-per-cent accuracy in detecting HIV in people who do, indeed, have the virus.

"So obviously, this new test will provide an alternative mechanism of allowing people to get tested," Paol says.

"Just as having access to this test will probably reduce HIV transmission."

The OraQuick test involves swabbing one's upper and lower gums with a stick and dipping it into a vial of solution. One line of color

Paol determined in a study that the test is 100-per-cent accurate in high-risk groups. However, other researchers have found that 92 per cent of the time the test is accurate in detecting HIV in people who do, indeed, have the virus.

That's because the test picks up antibodies that the immune system develops to counteract HIV, and it can take up to three months for antibodies to show up after one contracts the virus - a period during which one can take the test and get a so-called false-negative result.

In yet another study Paol carried out, she proved that

Anti-retroviral drugs given to an HIV-exposed partner after birth can prevent infection. But a pregnant woman must be tested before or during labour - something that rarely occurred in rural India because of AIDS stigmatization.

"So HIV tests are much needed to find out which sexual partners, and there will be the best approach that will probably help individuals who are not getting tested to slow worldwide," she said.

Paol has just completed an HIV self-testing study on Montreal's downtown

would not confirm whether the federal government is evaluating the test, saying that "any information to discuss applications are considered confidential."

The Public Health Agency of Canada estimates that there are 60,000 people living with HIV in the country's 32 million people - or 20 per cent - are unaware of their infection.

Orion Technologies, the manufacturer of the test, expects to sell 500 kits online and in 50,000 pharmacies as of October.

## Synergistic Innovative HIV Self testing Strategy

- # Highest HIV prevalence 5.3 million in the world!  
(22% of global HIV burden)
- # Affected populations include:
  - # Migrant workers, Young women
- # A long history of AIDS denialism (1983-)
- # About 50% of population do not seek facility-based testing –shame, stigma, discrimination, long wait times, delays in linkages to care
- # **A personalized tailored screening** option.



# CONCERNS

1. Can people self test without errors?
2. What about accuracy of these tests?



## Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis



Nitika Pant Pai, Bhairavi Balram, Sushmita Shivkumar, Jorge Luis Martinez-Cajas, Christiane Claessens, Gilles Lambert, Rosanna W Peeling, Lawrence Joseph

### Summary

**Background** The focus on prevention strategies aimed at curbing the HIV epidemic is growing, and therefore screening for HIV has again taken centre stage. Our aim was to establish whether a convenient, non-invasive, HIV test that uses oral fluid was accurate by comparison with the same test with blood-based specimens.

**Methods** We did a systematic review and meta-analysis to compare the diagnostic accuracy of a rapid HIV-antibody-based point-of-care test (Oraquick advance rapid HIV-1/2, OraSure Technologies Inc, PA, USA) when used with oral versus blood-based specimens in adults. We searched five databases of published work and databases of five key HIV conferences. Studies we deemed eligible were those focused on adults at risk of HIV; we excluded studies in children, in co-infected populations, with self-reported inferior reference standards, and with incomplete reporting of key data items. We assessed the diagnostic accuracy of testing with oral and blood-based specimens with bivariate regression analysis. We computed positive predictive values (PPVs) in high-prevalence and low-prevalence settings with Bayesian methods.

**Findings** In a direct head-to-head comparison of studies, we identified a pooled sensitivity about 2% lower in oral

Published Online  
January 24, 2012  
DOI:10.1016/S1473-3099(11)70368-1

See Online/Correspondence  
DOI:10.1016/S1473-3099(12)70000-0

Department of  
McGill University  
Clinical Epidemiology  
Infectious Disease  
University Health  
Montreal, QC, Canada  
(N Pant Pai MD, S Shivkumar MA, Infectious Disease)

**Funding** Canadian Institutes for Health Research (CIHR KRS 102067).

[www.thelancet.com/infection](http://www.thelancet.com/infection) Published online January 24, 2012 DOI:10.1016/S1473-3099(11)70368-1

## Saliva Legit for HIV Testing

A quick spit test is as good as blood for detecting HIV, and could encourage self-testing initiatives in the US and Africa.

By Megan Scudellari | January 25, 2012



OraQuick HIV test


A pain-free, non-invasive saliva test is as accurate as a traditional blood test to diagnose infections of the human immunodeficiency virus (HIV), according to a [new meta-analysis](#) published yesterday (January 24) in *The Lancet Infectious Diseases*. The test could be a solution for countries that wish to adopt self-testing strategies for HIV.

Pooling data from five worldwide databases, an international team of researchers found that [Oraquick HIV-1/2](#), a saliva test sold by Pennsylvania-based OraSure

Home > HIV Special Report > Article >

## Oral HIV test results found to be less reliable

HARRIET MCLEA | 24 January, 2012 00:22



A new study on oral HIV tests has added fire to the debate on whether self-testing should be allowed in South Africa.

A NEW study on oral HIV tests has added fire to the debate on whether self-testing should be allowed in South Africa.

The study, which compared the accuracy of testing for HIV using cheek and gum tissue (oral mucosal transudate) to blood tests, was



## Saliva HIV test as accurate as blood screening

ANI Jan 25, 2012, 05:36PM IST

Tags: saliva test | saliva | McGill University | HIV

*Researchers including one of an Indian origin have revealed that saliva test used to diagnose the human immunodeficiency virus (HIV), is comparable in accuracy to the traditional blood test.*

A new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University found that the saliva HIV test, OraQuick HIV1/2, had the same accuracy as the blood test for high-risk populations.



(Saliva HIV test as accurate as blood screening (Thinkstock photos/Getty Images))



FDA approved in home oral HIV self test July 2012



Nitika Pant Pai, MD, MPH, PhD  
Assistant Professor  
Clinical Epidemiology & Infectious Diseases  
Faculty of Medicine  
McGill University and Health Centre  
Email: nitika.pai@mcgill.ca  
Website : www.nitikapantpai.com

Self Testing Strategy

# A VISION

# Self Testing Strategies

## 2 Kinds of Strategies



### **Unsupervised self testing:**

Participants understand pre test information, conduct and interpret self test, and call the counselor for post test linkages

### **Facilitated or supervised self testing:**

with aid of counselors, educators in a supervised setting, where the self testing process is conducted by the participant in a kiosk.

# Supervised and Unsupervised Self-Testing for HIV in High- and Low-Risk Populations: A Systematic Review

Nitika Pant Pai<sup>1\*</sup>, Jigyasa Sharma<sup>2</sup>, Sushmita Shivkumar<sup>1</sup>, Sabrina Pillay<sup>1</sup>, Caroline Vadnais<sup>1</sup>, Lawrence Joseph<sup>2</sup>, Keertan Dheda<sup>3</sup>, Rosanna W. Peeling<sup>4</sup>

**1** Division of Clinical Epidemiology, McGill University Health Centre, Department of Medicine, McGill University, Montreal, Canada, **2** Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada, **3** Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa, **4** London School of Hygiene and Tropical Medicine, London, United Kingdom

## Abstract

**Background:** Stigma, discrimination, lack of privacy, and long waiting times partly explain why six out of ten individuals living with HIV do not access facility-based testing. By circumventing these barriers, self-testing offers potential for more people to know their sero-status. Recent approval of an in-home HIV self test in the US has sparked self-testing initiatives, yet data on acceptability, feasibility, and linkages to care are limited. We systematically reviewed evidence on supervised (self-testing aided by a health care professional) and unsupervised (performed by self-tester with access to phone/internet counselling) self-testing strategies.

**Methods and Findings:** Seven databases (Medline [via PubMed], Biosis, PsycINFO, Cinahl, African Medicus, LILACS, and EMBASE) and conference abstracts of six major HIV/sexually transmitted infections conferences were searched from 1st January 2000–30th October 2012. 1,221 citations were identified and 21 studies included for review. Seven studies evaluated an unsupervised strategy and 14 evaluated a supervised strategy. For both strategies, data on acceptability (range: 74%–96%), preference (range: 61%–91%), and partner self-testing (range: 80%–97%) were high. A high specificity (range: 99.8%–100%) was observed for both strategies, while a lower sensitivity was reported in the unsupervised (range: 92.9%–100%; one study) versus supervised (range: 97.4%–97.9%; three studies) strategy. Regarding feasibility of linkage to counselling and care, 96% ( $n = 102/106$ ) of individuals testing positive for HIV stated they would seek post-test counselling (unsupervised strategy, one study). No extreme adverse events were noted. The majority of data ( $n = 11,019/12,402$  individuals, 89%) were from high-income settings and 71% ( $n = 15/21$ ) of studies were cross-sectional in design, thus limiting our analysis.

**Conclusions:** Both supervised and unsupervised testing strategies were highly acceptable, preferred, and more likely to result in partner self-testing. However, no studies evaluated post-test linkage with counselling and treatment outcomes and reporting quality was poor. Thus, controlled trials of high quality from diverse settings are warranted to confirm and extend these findings.

Please see later in the article for the Editors' Summary.



**UNAIDS**  
 JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS

UNHCR  
 UNICEF  
 WFP  
 UNDP  
 UNFPA

UNODC  
 ILO  
 UNESCO  
 WHO  
 WORLD BANK



The real world from a self-administered HIV test kit sits on the desk in Dr. Melissa Potts' office at McGill University. She is leading an international study on the use of home HIV tests as a first step against the disease.

## Home HIV test could help prevent spread: study

McGill researcher sees global impact

By [Name] [Date]

It was rather like a million uses in a row of your home or mobile

study involved 22 nations world-wide, including Africa, South America, Europe and India.

A rapid home test based on a saliva sample or a blood drop from a finger would introduce diagnosis in a simpler way that better fitting low-cost-for-progressives, she said.

Both tests are convenient, easy-to-use and fast — about 30 minutes for results — and a

simple one, the study found. But she cautioned that home screening must be coupled with counseling and referral services. Still, the test should be given to people who are at risk of HIV infection, she said.

While currently unavailable in Canada, the quick test may be available in the U.S. by next



# SOUTH AFRICA: Self-Test

## Health Care Professionals



An innovative  
unsupervised self-  
testing strategy



Oral Test ● Internet ● Computers ● Mobile Phone  
● Public Health ● Synergy ●



# SELF TESTING: THE MIDDLE PATH

- # An alternative that will expand the reach of conventional testing; engagement and improving access to testing marginalized communities; linked treatment solutions
- # Non- judgemental, proactive, confidential; careful guided introduction; private;
- # Each country requires its own strategic set ups, linkages, networks

# POCT BARRIERS PROJECT

2012-

OPEN ACCESS Freely available online

 PLOS | MEDICINE

Policy Forum


## Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income Countries

**Nitika Pant Pai<sup>1</sup>, Caroline Vadnais<sup>2</sup>, Claudia Denkinger<sup>2,3</sup>, Nora Engel<sup>4</sup>, Madhukar Pai<sup>2,5\*</sup>**

**1** Division of Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Canada, **2** Respiratory Epidemiology & Clinical Research Unit, Montreal Chest Institute, Montreal, Canada, **3** Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, **4** Department of Health, Ethics and Society/Caphri, Faculty of Health, Medicine and Life Sciences, Maastricht University, The Netherlands, **5** Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada

BILL & MELINDA  
GATES foundation





“There is no end to learning. When we feel that we have learned everything, it means that we have learned nothing.”

- Kenosha Furuya

# ACKNOWLEDGEMENTS

# *CIHR New Investigator Award 2010*

# *Grand Challenges Canada Stars in Global Health Award 2011*

# *Chanchlani Global Health Research Award 2012 McMaster University*

# *Maude Abbott Award, McGill University 2013*

